Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
AstraZeneca
Boehringer Ingelheim
Baxter
Harvard Business School

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR DAYTRANA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Daytrana

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00434213 ↗ Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA Completed Noven Therapeutics Phase 4 2007-01-01 This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks.
NCT00499863 ↗ Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD Completed Noven Therapeutics Phase 3 2007-07-01 To assess the efficacy and safety of efficacy of MTS compared to placebo
NCT00501293 ↗ Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD Completed Noven Therapeutics Phase 3 2007-08-01 To evaluate the long-term, safety of Methylphenidate Transdermal System (MTS) in aged 13-17 years diagnosed withADHD
NCT00506285 ↗ Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD Completed Shire Phase 3 2007-06-01 This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in treating adult ADHD. MTS has received FDA approval for childhood ADHD but this is the first trial for adult ADHD. Subjects will experience two screening visits and one baseline visit. Those who meet admission criteria will enter the double-blind phase. This will involve two 4-week treatment periods one of which will involve the use of MTS and the other a placebo patch. Subjects who complete the double-blind phase will be allowed to enter a 180-day, open-label MTS phase designed to assess long-term effects.
NCT00506285 ↗ Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD Completed University of Utah Phase 3 2007-06-01 This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in treating adult ADHD. MTS has received FDA approval for childhood ADHD but this is the first trial for adult ADHD. Subjects will experience two screening visits and one baseline visit. Those who meet admission criteria will enter the double-blind phase. This will involve two 4-week treatment periods one of which will involve the use of MTS and the other a placebo patch. Subjects who complete the double-blind phase will be allowed to enter a 180-day, open-label MTS phase designed to assess long-term effects.
NCT00541346 ↗ A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms Completed Mark L. Wolraich, M.D. Phase 3 2007-09-01 This is an open-label study of the efficacy of Daytrana (methylphenidate transdermal system) for the treatment of attention and behavioral symptoms in children with Autism Spectrum Disorders. Twenty patients will be enrolled and treated with 10-30 mg of Daytrana for a total of eight weeks. Changes in core hyperactivity, impulsivity, and inattention symptoms, autism spectrum symptoms and functional outcomes will be assessed. Acceptability of the transdermal route of administration in this population will also be assessed. The researchers hypothesize that Daytrana is a safe and effective medication for children with Autism Spectrum Disorders who have symptoms of inattention, hyperactivity and impulsivity.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Daytrana

Condition Name

Condition Name for Daytrana
Intervention Trials
Attention Deficit Hyperactivity Disorder 7
ADHD 3
Prostate Carcinoma 1
Attention Deficit Disorder With Hyperactivity 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Daytrana
Intervention Trials
Attention Deficit Disorder with Hyperactivity 11
Hyperkinesis 8
Fatigue 2
Delayed Emergence from Anesthesia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Daytrana

Trials by Country

Trials by Country for Daytrana
Location Trials
United States 70
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Daytrana
Location Trials
Texas 5
Ohio 4
Virginia 4
Kentucky 3
Arizona 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Daytrana

Clinical Trial Phase

Clinical Trial Phase for Daytrana
Clinical Trial Phase Trials
Phase 4 5
Phase 3 5
Phase 2/Phase 3 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Daytrana
Clinical Trial Phase Trials
Completed 10
Recruiting 2
Terminated 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Daytrana

Sponsor Name

Sponsor Name for Daytrana
Sponsor Trials
Noven Therapeutics 3
National Cancer Institute (NCI) 2
M.D. Anderson Cancer Center 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Daytrana
Sponsor Trials
Other 14
Industry 5
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
AstraZeneca
Merck
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.